1
|
Purgatorio R, Boccarelli A, Pisani L, de Candia M, Catto M, Altomare CD. A Critical Appraisal of the Protective Activity of Polyphenolic Antioxidants against Iatrogenic Effects of Anticancer Chemotherapeutics. Antioxidants (Basel) 2024; 13:133. [PMID: 38275658 PMCID: PMC10812703 DOI: 10.3390/antiox13010133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 01/15/2024] [Accepted: 01/15/2024] [Indexed: 01/27/2024] Open
Abstract
Polyphenolic compounds, encompassing flavonoids (e.g., quercetin, rutin, and cyanidin) and non-flavonoids (e.g., gallic acid, resveratrol, and curcumin), show several health-related beneficial effects, which include antioxidant, anti-inflammatory, hepatoprotective, antiviral, and anticarcinogenic properties, as well as the prevention of coronary heart diseases. Polyphenols have also been investigated for their counteraction against the adverse effects of common anticancer chemotherapeutics. This review evaluates the outcomes of clinical studies (and related preclinical data) over the last ten years, with a focus on the use of polyphenols in chemotherapy as auxiliary agents acting against oxidative stress toxicity induced by antitumor drugs. While further clinical studies are needed to establish adequate doses and optimal delivery systems, the improvement in polyphenols' metabolic stability and bioavailability, through the implementation of nanotechnologies that are currently being investigated, could improve therapeutic applications of their pharmaceutical or nutraceutical preparations in tumor chemotherapy.
Collapse
Affiliation(s)
- Rosa Purgatorio
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70125 Bari, Italy; (R.P.); (L.P.); (M.d.C.); (M.C.)
| | - Angelina Boccarelli
- Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy;
| | - Leonardo Pisani
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70125 Bari, Italy; (R.P.); (L.P.); (M.d.C.); (M.C.)
| | - Modesto de Candia
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70125 Bari, Italy; (R.P.); (L.P.); (M.d.C.); (M.C.)
| | - Marco Catto
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70125 Bari, Italy; (R.P.); (L.P.); (M.d.C.); (M.C.)
| | - Cosimo D. Altomare
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, via E. Orabona 4, 70125 Bari, Italy; (R.P.); (L.P.); (M.d.C.); (M.C.)
| |
Collapse
|
2
|
Masci D, Puxeddu M, Di Magno L, D’Ambrosio M, Parisi A, Nalli M, Bai R, Coluccia A, Sciò P, Orlando V, D’Angelo S, Biagioni S, Urbani A, Hamel E, Nocentini A, Filiberti S, Turati M, Ronca R, Kopecka J, Riganti C, Fionda C, Bordone R, Della Rocca G, Canettieri G, Supuran CT, Silvestri R, La Regina G. 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1 H-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/β-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells. J Med Chem 2023; 66:14824-14842. [PMID: 37902628 PMCID: PMC10641813 DOI: 10.1021/acs.jmedchem.3c01424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 10/11/2023] [Accepted: 10/12/2023] [Indexed: 10/31/2023]
Abstract
We synthesized new pyrrole and indole derivatives as human carbonic anhydrase (hCA) inhibitors with the potential to inhibit the Wnt/β-catenin signaling pathway. The presence of both N1-(4-sulfonamidophenyl) and 3-(3,4,5-trimethoxyphenyl) substituents was essential for strong hCA inhibitors. The most potent hCA XII inhibitor 15 (Ki = 6.8 nM) suppressed the Wnt/β-catenin signaling pathway and its target genes MYC, Fgf20, and Sall4 and exhibited the typical markers of apoptosis, cleaved poly(ADP-ribose)polymerase, and cleaved caspase-3. Compound 15 showed strong inhibition of viability in a panel of cancer cells, including colorectal cancer and triple-negative breast cancer cells, was effective against the NCI/ADR-RES DOX-resistant cell line, and restored the sensitivity to doxorubicin (DOX) in HT29/DX and MDCK/P-gp cells. Compound 15 is a novel dual-targeting compound with activity against hCA and Wnt/β-catenin. It thus has a broad targeting spectrum and is an anticancer agent with specific potential in P-glycoprotein overexpressing cell lines.
Collapse
Affiliation(s)
- Domiziana Masci
- Department
of Basic Biotechnological Sciences, Intensivological and Perioperative
Clinics, Catholic University of the Sacred
Heart, Largo Francesco
Vito 1, Rome 00168, Italy
| | - Michela Puxeddu
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| | - Laura Di Magno
- Laboratory
Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti,
Department of Molecular Medicine, Sapienza
University of Rome, Viale
Regina Elena 291, Rome 00161, Italy
| | - Michele D’Ambrosio
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| | - Anastasia Parisi
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| | - Marianna Nalli
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| | - Ruoli Bai
- Molecular
Pharmacology Branch, Developmental Therapeutics Program, Division
of Cancer Treatment and Diagnosis, Frederick National Laboratory for
Cancer Research, National Cancer Institute,
National Institutes of Health, Frederick, Maryland 21702, United States
| | - Antonio Coluccia
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| | - Pietro Sciò
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| | - Viviana Orlando
- Department
of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy
| | - Sara D’Angelo
- Department
of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy
| | - Stefano Biagioni
- Department
of Biology and Biotechnologies “Charles Darwin”, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy
| | - Andrea Urbani
- Department
of Basic Biotechnological Sciences, Intensivological and Perioperative
Clinics, Catholic University of the Sacred
Heart, Largo Francesco
Vito 1, Rome 00168, Italy
| | - Ernest Hamel
- Molecular
Pharmacology Branch, Developmental Therapeutics Program, Division
of Cancer Treatment and Diagnosis, Frederick National Laboratory for
Cancer Research, National Cancer Institute,
National Institutes of Health, Frederick, Maryland 21702, United States
| | - Alessio Nocentini
- Dipartimento
Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy
| | - Serena Filiberti
- Experimental
Oncology and Immunology Unit, Department of Molecular and Translational
Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy
| | - Marta Turati
- Experimental
Oncology and Immunology Unit, Department of Molecular and Translational
Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy
| | - Roberto Ronca
- Experimental
Oncology and Immunology Unit, Department of Molecular and Translational
Medicine, University of Brescia, Via Branze 39, Brescia 25123, Italy
| | - Joanna Kopecka
- Department
of Oncology and Molecular Biotecnology Center “Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy
| | - Chiara Riganti
- Department
of Oncology and Molecular Biotecnology Center “Guido Tarone″, Oncological Pharmacology Unit, Via Nizza 44, Torino 10126, Italy
| | - Cinzia Fionda
- Laboratory
Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti,
Department of Molecular Medicine, Sapienza
University of Rome, Viale
Regina Elena 291, Rome 00161, Italy
| | - Rosa Bordone
- Laboratory
Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti,
Department of Molecular Medicine, Sapienza
University of Rome, Viale
Regina Elena 291, Rome 00161, Italy
| | - Giorgia Della Rocca
- Laboratory
Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti,
Department of Molecular Medicine, Sapienza
University of Rome, Viale
Regina Elena 291, Rome 00161, Italy
| | - Gianluca Canettieri
- Laboratory
Affiliated to Istituto Pasteur Italia—Fondazione Cenci Bolognetti,
Department of Molecular Medicine, Sapienza
University of Rome, Viale
Regina Elena 291, Rome 00161, Italy
| | - Claudiu T. Supuran
- Dipartimento
Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche, Universitá degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino I-50019, Firenze, Italy
| | - Romano Silvestri
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| | - Giuseppe La Regina
- Laboratory
Affiliated with the Institute Pasteur Italy—Cenci Bolognetti
Foundation, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Roma 00185, Italy
| |
Collapse
|
3
|
Yang Z, Cai Y, Mao S, Wu Q, Zhu M, Cao X, Wei B, Tian JM, Bao X, Ye X, Chen J, Wang S, Yu Y, Zhang H, Sun X, Cui ZN, Li YS, Wang H. Discovery of 2,5-disubstituted furan derivatives featuring a benzamide motif for overcoming P-glycoprotein mediated multidrug resistance in MCF-7/ADR cell. Eur J Med Chem 2023; 257:115462. [PMID: 37229830 DOI: 10.1016/j.ejmech.2023.115462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 05/05/2023] [Accepted: 05/05/2023] [Indexed: 05/27/2023]
Abstract
P-glycoprotein (P-gp) is one of the drug efflux transporters that triggers multidrug resistance (MDR) in cells. Herein, by utilizing the strategies of active skeleton splicing and structural optimization on the lead compound 5 m, a total of 50 novel 2,5-disubstituted furan derivatives were designed, synthesized, and screened for P-gp inhibitory activity. The structure-activity relationship analysis enabled the identification of an important pharmacophore N-phenylbenzamide, which resulted in the discovery of a promising drug lead compound Ⅲ-8. Ⅲ-8 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells. Western blot and Rh123 accumulation assay demonstrated that Ⅲ-8 displayed the reversal activity by inhibiting P-gp efflux. Molecular docking analysis indicated a potent affinity of Ⅲ-8 to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. Ⅲ-8 was determined to be a highly effective and safe P-gp inhibitor in an MCF-7/ADR xenograft mouse model.
Collapse
Affiliation(s)
- Zhikun Yang
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Yue Cai
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Shen Mao
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Qihao Wu
- Department of Chemistry, Yale University, New Haven, CT, 06520, USA; Institute of Biomolecular Design &Discovery, Yale University, West Haven, CT, 06516, USA
| | - Mengdi Zhu
- Research Center of Analysis and Measurement, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Xiaoji Cao
- Research Center of Analysis and Measurement, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Bin Wei
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Jin-Miao Tian
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Xiaoze Bao
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Xinyi Ye
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Jianwei Chen
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Sijia Wang
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Yanlei Yu
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Huawei Zhang
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Xuanrong Sun
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Zi-Ning Cui
- National Key Laboratory of Green Pesticide, Integrative Microbiology Research Centre, Guangdong Province Key Laboratory of Microbial Signals and Disease Control, College of Plant Protection, South China Agricultural University, Guangzhou, 510642, China.
| | - Ya-Sheng Li
- Department of Infectious Diseases & Anhui Center for Surveillance of Bacterial Resistance, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
| | - Hong Wang
- College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China.
| |
Collapse
|
4
|
Rybalkina EY, Moiseeva NI, Karamysheva AF, Eroshenko DV, Konysheva AV, Nazarov AV, Grishko VV. Triterpenoids with modified A-ring as modulators of P-gp-dependent drug-resistance in cancer cells. Chem Biol Interact 2021; 348:109645. [PMID: 34516973 DOI: 10.1016/j.cbi.2021.109645] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Revised: 08/13/2021] [Accepted: 09/06/2021] [Indexed: 12/29/2022]
Abstract
Semi-synthetic A-cycle modified triterpenic derivatives with A-cycle condensed with a heterocyclic fragment (compound 1) and fragmented A-ring (compound 2) were tested for cytotoxicity against several tumor cell cultures and doxorubicin (Dox)-resistant cell lines. The equal cytotoxicity of the tested compounds to the parental tumor cell lines (HBL-100, K562) and their resistant subclones (HBL-100/Dox, K562/i-S9) was revealed. The overexpression of ABCB1 (MDR1) gene and P-glycoprotein (P-gp) was confirmed for both resistant subclones of tumor cells. Compounds 1 and 2 were shown to inhibit the ABC-transporter gene expression (MDR1, MRP, MVP, and BCRP) and the transport of well-known P-gp substrate Rhodamine 123 from resistant cells. The docking of triterpenoids 1 and 2 into the drug binding site of P-gp revealed a similarity between the conformation of the tested triterpenoids and that of classical inhibitor verapamil, thus assuming these compounds to be more likely the inhibitors than the substrates of P-gp. Any tested triterpenic derivatives, when combined at non-toxic concentrations with doxorubicin, improved cytotoxic effect of the therapeutic drug against resistant subclones of tumor cells.
Collapse
Affiliation(s)
- Ekaterina Yu Rybalkina
- "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Kashirskoye shosse 24, 115478, Moscow, Russia
| | - Natalia I Moiseeva
- "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Kashirskoye shosse 24, 115478, Moscow, Russia
| | - Aida F Karamysheva
- "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Kashirskoye shosse 24, 115478, Moscow, Russia
| | - Daria V Eroshenko
- Institute of Technical Chemistry of Ural Branch of the Russian Academy of Sciences, Acad. Korolev St. 3, 614013, Perm, Russia
| | - Anastasia V Konysheva
- Institute of Technical Chemistry of Ural Branch of the Russian Academy of Sciences, Acad. Korolev St. 3, 614013, Perm, Russia
| | - Alexei V Nazarov
- Institute of Technical Chemistry of Ural Branch of the Russian Academy of Sciences, Acad. Korolev St. 3, 614013, Perm, Russia
| | - Victoria V Grishko
- Institute of Technical Chemistry of Ural Branch of the Russian Academy of Sciences, Acad. Korolev St. 3, 614013, Perm, Russia.
| |
Collapse
|
5
|
Del Coco L, Majellaro M, Boccarelli A, Cellamare S, Altomare CD, Fanizzi FP. Novel Antiproliferative Biphenyl Nicotinamide: NMR Metabolomic Study of its Effect on the MCF-7 Cell in Comparison with Cisplatin and Vinblastine. Molecules 2020; 25:E3502. [PMID: 32752035 PMCID: PMC7435671 DOI: 10.3390/molecules25153502] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/29/2020] [Accepted: 07/31/2020] [Indexed: 12/20/2022] Open
Abstract
A 1H-NMR-based metabolomic study was performed on MCF-7 cell lines treated with a novel nicotinamide derivative (DT-8) in comparison with two drugs characterized by a well-established mechanism of action, namely the DNA-metalating drug cisplatin (cis-diamminedichloridoplatinum(II), CDDP) and the antimitotic drug vinblastine (vinblastine, VIN). The effects of the three compounds, each one at the concentration corresponding to the IC50 value, were investigated, with respect to the controls (K), by the 1H-NMR of cells lysates and multivariate analysis (MVA) of the spectroscopic data. Relevant differences were found in the metabolic profiles of the different treatments with respect to the controls. A large overlap of the metabolic profiles in DT-8 vs. K and VIN vs. K suggests a similar biological response and mechanism of action, significantly diverse with respect to CDDP. On the other hand, DT8 seems to act by disorganizing the mitotic spindle and ultimately blocking the cell division, through a mechanism implying methionine depletion and/or S-adenosylmethionine (SAM) limitation.
Collapse
Affiliation(s)
- Laura Del Coco
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Prov.le Lecce-Monteroni, I-73100 Lecce, Italy;
| | - Maria Majellaro
- Department of Pharmacy–Pharmaceutical Sciences, University of Bari, Via Orabona 4, 70125 Bari, Italy; (M.M.); (S.C.); (C.D.A.)
- Department of Organic Chemistry, Faculty of Pharmacy, Center for Research in Biological Chemistry and Molecular Materials (CiQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Angelina Boccarelli
- Department of Biomedical Sciences and Human Oncology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Saverio Cellamare
- Department of Pharmacy–Pharmaceutical Sciences, University of Bari, Via Orabona 4, 70125 Bari, Italy; (M.M.); (S.C.); (C.D.A.)
| | - Cosimo Damiano Altomare
- Department of Pharmacy–Pharmaceutical Sciences, University of Bari, Via Orabona 4, 70125 Bari, Italy; (M.M.); (S.C.); (C.D.A.)
| | - Francesco Paolo Fanizzi
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Prov.le Lecce-Monteroni, I-73100 Lecce, Italy;
| |
Collapse
|
6
|
Dong J, Qin Z, Zhang WD, Cheng G, Yehuda AG, Ashby CR, Chen ZS, Cheng XD, Qin JJ. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. Drug Resist Updat 2020; 49:100681. [PMID: 32014648 DOI: 10.1016/j.drup.2020.100681] [Citation(s) in RCA: 147] [Impact Index Per Article: 36.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 01/13/2020] [Accepted: 01/16/2020] [Indexed: 12/16/2022]
Abstract
The presence of multidrug resistance (MDR) in malignant tumors is one of the primary causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding cassette (ABC) transporter, P-glycoprotein (P-gp), which significantly increases the efflux of certain anticancer drugs from tumor cells, produces MDR. Therefore, inhibition of P-gp may represent a viable therapeutic strategy to overcome cancer MDR. Over the past 4 decades, many compounds with P-gp inhibitory efficacy (referred to as first- and second-generation P-gp inhibitors) have been identified or synthesized. However, these compounds were not successful in clinical trials due to a lack of efficacy and/or untoward toxicity. Subsequently, third- and fourth-generation P-gp inhibitors were developed but dedicated clinical trials did not indicate a significant therapeutic effect. In recent years, an extraordinary array of highly potent, selective, and low-toxicity P-gp inhibitors have been reported. Herein, we provide a comprehensive review of the synthetic and natural products that have specific inhibitory activity on P-gp drug efflux as well as promising chemosensitizing efficacy in MDR cancer cells. The present review focuses primarily on the structural features, design strategies, and structure-activity relationships (SAR) of these compounds.
Collapse
Affiliation(s)
- Jinyun Dong
- Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Zuodong Qin
- Research Center of Biochemical Engineering Technology, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou 425199, China
| | - Wei-Dong Zhang
- School of Pharmacy, Naval Medical University, Shanghai, 200433, China
| | - Gang Cheng
- College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Assaraf G Yehuda
- The Fred Wyszkowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa, 3200003, Israel
| | - Charles R Ashby
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA
| | - Zhe-Sheng Chen
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
| | - Xiang-Dong Cheng
- Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
| | - Jiang-Jiang Qin
- Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China; College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
| |
Collapse
|
7
|
Hinge VK, Roy D, Kovalenko A. Prediction of P-glycoprotein inhibitors with machine learning classification models and 3D-RISM-KH theory based solvation energy descriptors. J Comput Aided Mol Des 2019; 33:965-971. [PMID: 31745705 DOI: 10.1007/s10822-019-00253-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Accepted: 11/14/2019] [Indexed: 11/24/2022]
Abstract
Development of novel in silico methods for questing novel PgP inhibitors is crucial for the reversal of multi-drug resistance in cancer therapy. Here, we report machine learning based binary classification schemes to identify the PgP inhibitors from non-inhibitors using molecular solvation theory with excellent accuracy and precision. The excess chemical potential and partial molar volume in various solvents are calculated for PgP± (PgP inhibitors and non-inhibitors) compounds with the statistical-mechanical based three-dimensional reference interaction site model with the Kovalenko-Hirata closure approximation (3D-RISM-KH molecular theory of solvation). The statistical importance analysis of descriptors identified the 3D-RISM-KH based descriptors as top molecular descriptors for classification. Among the constructed classification models, the support vector machine predicted the test set of Pgp± compounds with highest accuracy and precision of ~ 97% for test set. The validation of models confirms the robustness of state-of-the-art molecular solvation theory based descriptors in identification of the Pgp± compounds.
Collapse
Affiliation(s)
- Vijaya Kumar Hinge
- Department of Mechanical Engineering, 10-203 Donadeo Innovation Centre for Engineering, University of Alberta, 9211-116 Street NW, Edmonton, AB, T6G 1H9, Canada
| | - Dipankar Roy
- Department of Mechanical Engineering, 10-203 Donadeo Innovation Centre for Engineering, University of Alberta, 9211-116 Street NW, Edmonton, AB, T6G 1H9, Canada
| | - Andriy Kovalenko
- Department of Mechanical Engineering, 10-203 Donadeo Innovation Centre for Engineering, University of Alberta, 9211-116 Street NW, Edmonton, AB, T6G 1H9, Canada. .,Nanotechnology Research Centre, 11421 Saskatchewan Drive, Edmonton, AB, T6G 2M9, Canada.
| |
Collapse
|
8
|
3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance. Future Med Chem 2019; 11:2095-2106. [DOI: 10.4155/fmc-2019-0037] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Aim: Enamino 3-benzazecine compounds, incorporating the C6-C8 allene system, were synthesized and evaluated in vitro as inhibitors of P-glycoprotein (P-gp) and/or multidrug resistance-associated protein 1 (MRP1), two efflux pumps mainly connected with multidrug resistance (MDR) in cancer cells. Results & methodology: Most of the synthesized compounds were selective P-gp inhibitors in Calcein-AM uptake assay. Structure–activity relationships (SARs) pointed out that CO2Me derivatives are more potent than acetyl derivatives, and 10,11-dimethoxy compounds are five to tenfold more potent inhibitors than the respective unsubstituted compounds, and that the P-gp inhibition potency is mainly related to volume parameters. Conclusion: Nanomolar P-gp inhibitors, such as 23 (IC50 = 4.2 nM), restored the antiproliferative activity of doxorubicin in multidrug-resistant cells. The observed activities showed that 3-benzazecine-based compounds may be promising MDR reversers.
Collapse
|
9
|
Caron G, Kihlberg J, Ermondi G. Intramolecular hydrogen bonding: An opportunity for improved design in medicinal chemistry. Med Res Rev 2019; 39:1707-1729. [PMID: 30659634 DOI: 10.1002/med.21562] [Citation(s) in RCA: 81] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2018] [Revised: 12/18/2018] [Accepted: 12/19/2019] [Indexed: 12/14/2022]
Abstract
Recent literature shows that intramolecular hydrogen bond (IMHB) formation can positively impact upon the triad of permeability, solubility, and potency of drugs and candidates. IMHB modulation can be applied to compounds in any chemical space as a means for discovering drug candidates with both acceptable potency and absorption, distribution, metabolism, and excretion-Tox profiles. Integrating IMHB formation in design of drugs is, therefore, an exciting and timely challenge for modern medicinal chemistry. In this review, we first provide some background about IMHBs from the medicinal chemist's point of view and highlight some IMHB-associated misconceptions. Second, we propose a classification of IMHBs for drug discovery purposes, review the most common in silico tactics to include IMHBs in lead optimization and list some experimental physicochemical descriptors, which quantify the propensity of compounds to form IMHBs. By focusing on the compounds size and the number of IMHBs that can potentially be formed, we also outline the major difficulties encountered when designing compounds based on the inclusion of IMHBs. Finally, we discuss recent case studies illustrating the application of IMHB to optimize cell permeability and physicochemical properties of small molecules, cyclic peptides and macrocycles.
Collapse
Affiliation(s)
- Giulia Caron
- Molecular Biotechnology and Health Sciences Department, University of Torino, Torino, Italy
| | - Jan Kihlberg
- Department of Chemistry - BMC, Uppsala University, Uppsala, Sweden
| | - Giuseppe Ermondi
- Molecular Biotechnology and Health Sciences Department, University of Torino, Torino, Italy
| |
Collapse
|
10
|
Riganti C, Contino M, Guglielmo S, Perrone MG, Salaroglio IC, Milosevic V, Giampietro R, Leonetti F, Rolando B, Lazzarato L, Colabufo NA, Fruttero R. Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. J Med Chem 2018; 62:974-986. [DOI: 10.1021/acs.jmedchem.8b01655] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Chiara Riganti
- Dipartimento di Oncologia, Università degli Studi di Torino, Via Santena 5/bis, 10126 Torino, Italy
| | - Marialessandra Contino
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
| | - Stefano Guglielmo
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via P. Giuria 9, 10125 Torino, Italy
| | - Maria G. Perrone
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
| | - Iris C. Salaroglio
- Dipartimento di Oncologia, Università degli Studi di Torino, Via Santena 5/bis, 10126 Torino, Italy
| | - Vladan Milosevic
- Dipartimento di Oncologia, Università degli Studi di Torino, Via Santena 5/bis, 10126 Torino, Italy
| | - Roberta Giampietro
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
| | - Francesco Leonetti
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
| | - Barbara Rolando
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via P. Giuria 9, 10125 Torino, Italy
| | - Loretta Lazzarato
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via P. Giuria 9, 10125 Torino, Italy
| | - Nicola A. Colabufo
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
- Biofordrug s.r.l., Spin-off dell’Università degli Studi di Bari ALDO MORO, Via Orabona 4, 70125 Bari, Italy
| | - Roberta Fruttero
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via P. Giuria 9, 10125 Torino, Italy
| |
Collapse
|
11
|
Porcelli L, Stolfa D, Stefanachi A, Di Fonte R, Garofoli M, Iacobazzi RM, Silvestris N, Guarini A, Cellamare S, Azzariti A. Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. Cancer Lett 2018; 445:1-10. [PMID: 30583077 DOI: 10.1016/j.canlet.2018.12.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 12/05/2018] [Accepted: 12/11/2018] [Indexed: 12/16/2022]
Abstract
We previously demonstrated that some N-biphenylanilides caused cell-cycle arrest at G2/M transition in breast cancer cells. Among them we choose three derivatives, namely PTA34, PTA73 and RS35 for experimentation in solid tumor cell lines, classical Hodgkin Lymphoma (cHL) cell lines and bona fide normal cell lines. Almost all tumor cells were sensitive to compounds in the nanomolar range whereas, they were not cytotoxic to normal ones. Interestingly the compounds caused a strong G2/M phase arrest in cHL cell lines, thus, here we investigated whether they affected the integrity of microtubules in such cells. We found that they induced a long prometaphase arrest, followed by induction of apoptosis which involved mitochondria. PTA73 and RS35 induced the mitotic arrest through the fragmentation of microtubules which prevented the kinethocore-mitotic spindle interaction and the exit from mitosis. PTA34 is instead a tubulin-targeting agent because it inhibited the tubulin polymerization as vinblastine. As such, PTA34 maintained the Cyclin B1-CDK1 regulatory complex activated during the G2/M arrest while inducing the inactivation of Bcl-2 through phosphorylation in Ser70, the degradation of Mcl-1 and a strong activation of BIML and BIMS proapoptotic isoforms. In addition PTA34 exerted an antiangiogenic effect by suppressing microvascular formation.
Collapse
Affiliation(s)
- L Porcelli
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - D Stolfa
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy; Dipartimento di Farmacia-Scienza del Farmaco, Università di Bari, Bari, Italy
| | - A Stefanachi
- Dipartimento di Farmacia-Scienza del Farmaco, Università di Bari, Bari, Italy
| | - R Di Fonte
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - M Garofoli
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - R M Iacobazzi
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - N Silvestris
- Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - A Guarini
- Haematology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - S Cellamare
- Dipartimento di Farmacia-Scienza del Farmaco, Università di Bari, Bari, Italy
| | - A Azzariti
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
| |
Collapse
|
12
|
Guberović I, Marjanović M, Mioč M, Ester K, Martin-Kleiner I, Šumanovac Ramljak T, Mlinarić-Majerski K, Kralj M. Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells. Sci Rep 2018; 8:14467. [PMID: 30262858 PMCID: PMC6160470 DOI: 10.1038/s41598-018-32770-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Accepted: 09/12/2018] [Indexed: 01/02/2023] Open
Abstract
Multidrug resistance (MDR) is a widespread phenomenon exhibited by many cancers and represents a fundamental obstacle for successful cancer treatments. Tumour cells commonly achieve MDR phenotype through overexpression and/or increased activity of ABC transporters. P-glycoprotein transporter (P-gp, ABCB1) is a major cause of MDR and therefore represents a valuable target for MDR reversal. Several naturally occurring potassium ionophores (e.g. salinomycin) were shown to inhibit P-gp effectively. We have previously shown antitumour activity of a number of 18-crown-6 ether compounds that transport potassium ions across membranes. Here we present data on P-gp inhibitory activity of 16 adamantane-substituted monoaza- and diaza-18-crown-6 ether compounds, and their effect on MDR reversal in model cell lines. We show that crown ether activity depends on their lipophilicity as well as on the linker to adamantane moiety. The most active crown ethers were shown to be more effective in sensitising MDR cells to paclitaxel and adriamycin than verapamil, a well-known P-gp inhibitor. Altogether our data demonstrate a novel use of crown ethers for inhibition of P-gp and reversal of MDR phenotype.
Collapse
Affiliation(s)
- Iva Guberović
- Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, 10 000, Zagreb, Croatia.,Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol-Universitat Autònoma de Barcelona, 08916, Badalona, Spain
| | - Marko Marjanović
- Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, 10 000, Zagreb, Croatia
| | - Marija Mioč
- Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, 10 000, Zagreb, Croatia
| | - Katja Ester
- Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, 10 000, Zagreb, Croatia
| | - Irena Martin-Kleiner
- Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, 10 000, Zagreb, Croatia
| | - Tatjana Šumanovac Ramljak
- Department of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička cesta 54, 10000, Zagreb, Croatia
| | - Kata Mlinarić-Majerski
- Department of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička cesta 54, 10000, Zagreb, Croatia
| | - Marijeta Kralj
- Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička cesta 54, 10 000, Zagreb, Croatia.
| |
Collapse
|
13
|
Nevskaya AA, Matveeva MD, Borisova TN, Niso M, Colabufo NA, Boccarelli A, Purgatorio R, de Candia M, Cellamare S, Voskressensky LG, Altomare CD. A New Class of 1-Aryl-5,6-dihydropyrrolo[2,1-a]isoquinoline Derivatives as Reversers of P-Glycoprotein-Mediated Multidrug Resistance in Tumor Cells. ChemMedChem 2018; 13:1588-1596. [PMID: 29802687 DOI: 10.1002/cmdc.201800177] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Revised: 05/16/2018] [Indexed: 12/20/2022]
Abstract
A number of aza-heterocyclic compounds, which share the 5,6-dihydropyrrolo[2,1-a]isoquinoline (DHPIQ) scaffold with members of the lamellarin alkaloid family, were synthesized and evaluated for their ability to reverse in vitro multidrug resistance in cancer cells through inhibition of P-glycoprotein (P-gp) and/or multidrug-resistance-associated protein 1. Most of the investigated DHPIQ compounds proved to be selective P-gp modulators, and the most potent modulator, 8,9-diethoxy-1-(3,4-diethoxyphenyl)-3-(furan-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-2-carbaldehyde, attained sub-micromolar inhibitory potency (IC50 : 0.19 μm). Schiff bases prepared by the condensation of some 1-aryl-DHPIQ aldehydes with p-aminophenol also proved to be of some interest, and one of them, 4-((1-(4-fluorophenyl)-5,6-dihydro-8,9-dimethoxypyrrolo[2,1-a]isoquinolin-2-yl)methyleneamino)phenol, had an IC50 value of 1.01 μm. In drug combination assays in multidrug-resistant cells, some DHPIQ compounds, at nontoxic concentrations, significantly increased the cytotoxicity of doxorubicin in a concentration-dependent manner. Studies of structure-activity relationships and investigation of the chemical stability of Schiff bases provided physicochemical information useful for molecular optimization of lamellarin-like cytotoxic drugs active toward chemoresistant tumors as well as nontoxic reversers of P-gp-mediated multidrug resistance in tumor cells.
Collapse
Affiliation(s)
- Alisa A Nevskaya
- Organic Chemistry Department, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow, 117198, Russia
| | - Maria D Matveeva
- Organic Chemistry Department, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow, 117198, Russia
| | - Tatiana N Borisova
- Organic Chemistry Department, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow, 117198, Russia
| | - Mauro Niso
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Nicola A Colabufo
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Angelina Boccarelli
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Rosa Purgatorio
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Modesto de Candia
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Saverio Cellamare
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| | - Leonid G Voskressensky
- Organic Chemistry Department, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow, 117198, Russia
| | - Cosimo D Altomare
- Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125, Bari, Italy
| |
Collapse
|
14
|
Fournier JF, Clary L, Chambon S, Dumais L, Harris CS, Millois C, Pierre R, Talano S, Thoreau É, Aubert J, Aurelly M, Bouix-Peter C, Brethon A, Chantalat L, Christin O, Comino C, El-Bazbouz G, Ghilini AL, Isabet T, Lardy C, Luzy AP, Mathieu C, Mebrouk K, Orfila D, Pascau J, Reverse K, Roche D, Rodeschini V, Hennequin LF. Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne. J Med Chem 2018; 61:4030-4051. [DOI: 10.1021/acs.jmedchem.8b00067] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jean-François Fournier
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Laurence Clary
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Sandrine Chambon
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Laurence Dumais
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Craig Steven Harris
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Corinne Millois
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Romain Pierre
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Sandrine Talano
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Étienne Thoreau
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Jérome Aubert
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Michèle Aurelly
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Claire Bouix-Peter
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Anne Brethon
- Edelris, 115 Avenue Lacassagne, 69003 Lyon, France
| | - Laurent Chantalat
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Olivier Christin
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Catherine Comino
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Ghizlane El-Bazbouz
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Anne-Laurence Ghilini
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Tatiana Isabet
- Synchrotron Soleil, L’Orme des Merisiers, Saint-Aubin, BP 48, 91192 Gif-sur-Yvette Cedex, France
| | - Claude Lardy
- Edelris, 115 Avenue Lacassagne, 69003 Lyon, France
| | - Anne-Pascale Luzy
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Céline Mathieu
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Kenny Mebrouk
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Danielle Orfila
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Jonathan Pascau
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Kevin Reverse
- Nestlé Skin Health R&D, 2400 Route des Colles, BP 87, 06902 Sophia-Antipolis Cedex, France
| | - Didier Roche
- Edelris, 115 Avenue Lacassagne, 69003 Lyon, France
| | | | | |
Collapse
|
15
|
Syed SB, Arya H, Fu IH, Yeh TK, Periyasamy L, Hsieh HP, Coumar MS. Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep 2017; 7:7972. [PMID: 28801675 PMCID: PMC5554262 DOI: 10.1038/s41598-017-08062-2] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Accepted: 07/04/2017] [Indexed: 01/08/2023] Open
Abstract
P-glycoprotein (P-gp) is a drug transporter that effluxes chemotherapeutic drugs and is implicated in the development of resistance of cancer cells to chemotherapeutic drugs. To date, no drug has been approved to inhibit P-gp and restore chemotherapy efficacy. Moreover, majority of the reported inhibitors have high molecular weight and complex structures, making it difficult to understand the basic structural requirement for P-gp inhibition. In this study, two structurally simple, low molecular weight piperine analogs Pip1 and Pip2 were designed and found to better interact with P-gp than piperine in silico. A one step, acid-amine coupling reaction between piperic acid and 6,7-dimethoxytetrahydroisoquinoline or 2-(3,4-dimethoxyphenyl)ethylamine afforded Pip1 and Pip2, respectively. In vitro testing in drug resistant P-gp overexpressing KB (cervical) and SW480 (colon) cancer cells showed that both analogs, when co-administered with vincristine, colchicine or paclitaxel were able to reverse the resistance. Moreover, accumulation of P-gp substrate (rhodamine 123) in the resistant cells, a result of alteration of the P-gp efflux, was also observed. These investigations suggest that the natural product analog - Pip1 ((2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1 H)-yl)penta-2,4-dien-1-one) - is superior to piperine and could inhibit P-gp function. Further studies are required to explore the full potential of Pip1 in treating drug resistant cancer.
Collapse
Affiliation(s)
- Safiulla Basha Syed
- Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry, 605014, India
- DBT-Interdisciplinary Program in Life Sciences, Pondicherry University, Kalapet, Puducherry, 605014, India
| | - Hemant Arya
- Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry, 605014, India
| | - I-Hsuan Fu
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County, 350, Taiwan, ROC
| | - Teng-Kuang Yeh
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County, 350, Taiwan, ROC
| | - Latha Periyasamy
- Department of Biochemistry & Molecular Biology, School of Life Sciences, Pondicherry University, Kalapet, Puducherry, 605014, India
| | - Hsing-Pang Hsieh
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County, 350, Taiwan, ROC.
- Department of Chemistry, National Tsing Hua University, Hsinchu, 350, Taiwan, ROC.
| | - Mohane Selvaraj Coumar
- Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry, 605014, India.
| |
Collapse
|
16
|
Pisani L, De Palma A, Giangregorio N, Miniero DV, Pesce P, Nicolotti O, Campagna F, Altomare CD, Catto M. Mannich base approach to 5-methoxyisatin 3-(4-isopropylphenyl)hydrazone: A water-soluble prodrug for a multitarget inhibition of cholinesterases, beta-amyloid fibrillization and oligomer-induced cytotoxicity. Eur J Pharm Sci 2017; 109:381-388. [PMID: 28801274 DOI: 10.1016/j.ejps.2017.08.004] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 07/13/2017] [Accepted: 08/07/2017] [Indexed: 01/09/2023]
Abstract
Targeting protein aggregation for the therapy of neurodegenerative diseases remains elusive for medicinal chemists, despite a number of small molecules known to interfere in amyloidogenesis, particularly of amyloid beta (Aβ) protein. Starting from previous findings in the antiaggregating activity of a class of indolin-2-ones inhibiting Aβ fibrillization, 5-methoxyisatin 3-(4-isopropylphenyl)hydrazone 1 was identified as a multitarget inhibitor of Aβ aggregation and cholinesterases with IC50s in the low μM range. With the aim of increasing aqueous solubility, a Mannich-base functionalization led to the synthesis of N-methylpiperazine derivative 2. At acidic pH, an outstanding solubility increase of 2 over the parent compound 1 was proved through a turbidimetric method. HPLC analysis revealed an improved stability of the Mannich base 2 at pH2 along with a rapid release of 1 in human serum as well as an outstanding hydrolytic stability of the parent hydrazone. Coincubation of Aβ1-42 with 2 resulted in the accumulation of low MW oligomers, as detected with PICUP assay. Cell assays on SH-SY5Y cells revealed that 2 exerts strong cytoprotective effects in both cell viability and radical quenching assays, mainly related to its active metabolite 1. These findings show that 2 drives the formation of non-toxic, off-pathway Aβ oligomers unable to trigger the amyloid cascade and toxicity.
Collapse
Affiliation(s)
- Leonardo Pisani
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy
| | - Annalisa De Palma
- Dipartimento di Bioscienze, Biotecnologie e Biofarmaceutica, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy
| | - Nicola Giangregorio
- CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, via G. Amendola 165/A, I-70126 Bari, Italy
| | - Daniela V Miniero
- Dipartimento di Bioscienze, Biotecnologie e Biofarmaceutica, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy
| | - Paolo Pesce
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy
| | - Orazio Nicolotti
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy
| | - Francesco Campagna
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy
| | - Cosimo D Altomare
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy
| | - Marco Catto
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy.
| |
Collapse
|
17
|
Majellaro M, Stefanachi A, Tardia P, Vicenti C, Boccarelli A, Pannunzio A, Campanella F, Coluccia M, Denora N, Leonetti F, de Candia M, Altomare CD, Cellamare S. Investigating Structural Requirements for the Antiproliferative Activity of Biphenyl Nicotinamides. ChemMedChem 2017; 12:1380-1389. [PMID: 28665505 DOI: 10.1002/cmdc.201700365] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Indexed: 11/09/2022]
Abstract
A number of trimethoxybenzoic acid anilides, previously studied as permeability glycoprotein (P-gp) modulators, were screened with the aim of identifying new anticancer agents. One of these compounds, which showed antiproliferative activity against resistant MCF-7 cell line, was selected as the hit structure. Replacement of the trimethoxybenzoyl moiety with a nicotinoyl group, in order to overcome solubility issues, led to a new series of N-biphenyl nicotinoyl anilides, among which a nitro derivative, N-(3',5'-difluoro-3-nitro-[1,1'-biphenyl]-4-yl)nicotinamide (3), displayed antiproliferative activity against MCF-7 and MDA-MB-231 cells in the nanomolar range. The search for a bioisostere of the nitro group led to nitrile analogue N-(3-cyano-4'-fluoro-[1,1'-biphenyl]-4-yl)nicotinamide (36), which shows a strong increase in activity against MCF-7 and MDA-MB-231 cells. Compound 36 induced a dose-dependent accumulation of G2 - and M-phase MCF-7 cell populations, and a decrease in S-phase cells. Relative to vinblastine, a well-known potent antimitotic agent, compound 36 also induced G1 -phase arrest at low doses (20-40 nm), but did not inhibit in vitro tubulin polymerization.
Collapse
Affiliation(s)
- Maria Majellaro
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | - Angela Stefanachi
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | - Piero Tardia
- D3-Drug Discovery and Development Department, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy
| | - Chiara Vicenti
- Department of Emergency and Organ Transplantation, Section of Pathological Anatomy, University of Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Angelina Boccarelli
- Department of Biomedical Sciences and Human Oncology, University of Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy
| | - Alessandra Pannunzio
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | - Federica Campanella
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | - Mauro Coluccia
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | - Nunzio Denora
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | - Francesco Leonetti
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | - Modesto de Candia
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| | | | - Saverio Cellamare
- Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125, Bari, Italy
| |
Collapse
|
18
|
Computational modelling of efflux pumps and their inhibitors. Essays Biochem 2017; 61:141-156. [PMID: 28258237 DOI: 10.1042/ebc20160065] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2016] [Revised: 12/13/2016] [Accepted: 12/19/2016] [Indexed: 11/17/2022]
Abstract
Antimicrobial resistance is based on the multifarious strategies that bacteria adopt to face antibiotic therapies, making it a key public health concern of our era. Among these strategies, efflux pumps (EPs) contribute significantly to increase the levels and profiles of resistance by expelling a broad range of unrelated compounds - buying time for the organisms to develop specific resistance. In Gram-negative bacteria, many of these chromosomally encoded transporters form multicomponent 'pumps' that span both inner and outer membranes and are driven energetically by a primary or secondary transporter component.One of the strategies to reinvigorate the efficacy of antimicrobials is by joint administration with EP inhibitors (EPI), which either block the substrate binding and/or hinder any of the transport-dependent steps of the pump. In this review, we provide an overview of multidrug-resistance EPs, their inhibition strategies and the relevant findings from the various computational simulation studies reported to date with respect to deciphering the mechanism of action of inhibitors with the purpose of improving their rational design.
Collapse
|
19
|
Why we need to implement intramolecular hydrogen-bonding considerations in drug discovery. Future Med Chem 2017; 9:1-5. [DOI: 10.4155/fmc-2016-0195] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
20
|
Stefanachi A, Mangiatordi GF, Tardia P, Alberga D, Leonetti F, Niso M, Colabufo NA, Adamo C, Nicolotti O, Cellamare S. Design, synthesis, biological evaluation, NMR and DFT studies of structurally simplified trimethoxy benzamides as selective P-glycoprotein inhibitors: the role of molecular flatness. Chem Biol Drug Des 2016; 88:820-831. [DOI: 10.1111/cbdd.12811] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 03/31/2016] [Accepted: 06/18/2016] [Indexed: 01/13/2023]
Affiliation(s)
- Angela Stefanachi
- Dipartimento di Farmacia - Scienze del Farmaco; Università di Bari Aldo Moro; Bari Italy
| | | | - Piero Tardia
- Dipartimento di Farmacia - Scienze del Farmaco; Università di Bari Aldo Moro; Bari Italy
| | - Domenico Alberga
- Chimie ParisTech-CNRS; Institut de Recherche de Chimie Paris; PSL Research University; Paris France
- Institut Universitaire de France; Paris France
| | - Francesco Leonetti
- Dipartimento di Farmacia - Scienze del Farmaco; Università di Bari Aldo Moro; Bari Italy
| | - Mauro Niso
- Dipartimento di Farmacia - Scienze del Farmaco; Università di Bari Aldo Moro; Bari Italy
| | | | - Carlo Adamo
- Chimie ParisTech-CNRS; Institut de Recherche de Chimie Paris; PSL Research University; Paris France
- Institut Universitaire de France; Paris France
| | - Orazio Nicolotti
- Dipartimento di Farmacia - Scienze del Farmaco; Università di Bari Aldo Moro; Bari Italy
- Dipartimento di Fisica; INFN & TIRES; Università di Bari Aldo Moro; Bari Italy
| | - Saverio Cellamare
- Dipartimento di Farmacia - Scienze del Farmaco; Università di Bari Aldo Moro; Bari Italy
| |
Collapse
|
21
|
Measurement, Interpretation and Use of Free Ligand Solution Conformations in Drug Discovery. PROGRESS IN MEDICINAL CHEMISTRY 2016; 55:45-147. [DOI: 10.1016/bs.pmch.2015.10.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
22
|
Rankovic Z. CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. J Med Chem 2015; 58:2584-608. [DOI: 10.1021/jm501535r] [Citation(s) in RCA: 342] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Zoran Rankovic
- Eli Lilly and Company, 893 South
Delaware Street, Indianapolis, Indiana 46285, United States
| |
Collapse
|